Genetic variants of ApoE account for variability of plasma low-density lipoprotein and apolipoprotein B levels in FHBL.

Atherosclerosis

Division of Endocrinology, Metabolism, and Lipid Research, Washington University, School of Medicine, St. Louis, MO 63110, USA.

Published: January 2005


Category Ranking

98%

Total Visits

921

Avg Visit Duration

2 minutes

Citations

20

Article Abstract

We report two novel APOB mutations causing short apolipoprotein B (apoB) truncations undetectable in plasma and familial hypobetalipoproteinemia (FHBL). In Family 56, a 5 bp deletion in APOB exon 7 (870_874del5) causes a frame shift, converting tyrosine to a stop codon (Y220X) and producing an apoB-5 truncation. In Family 59, a point mutation (1941G>T) in APOB exon 13 converts glutamic acid to stop codon (E578X), specifying apoB-13. A recurrent mutation in exon 26 (4432delT) produces apoB-30.9 in Family 58. In some members of these families, we observed that plasma low-density lipoprotein (LDL) cholesterol and apoB levels were unusually low even for subjects heterozygous for FHBL. To ascertain whether genetic variations in apolipoprotein E (apoE) would explain some of the variations of apoB and LDL cholesterol levels, apoE genotypes were assessed in affected subjects from a total of eight FHBL families with short apoB truncations. Heterozygous FHBL with the epsilon3/epsilon4 genotype had 10-1 5mg/dL higher plasma LDL cholesterol and apoB levels compared to subjects with the epsilon2/epsilon3 and epsilon3/epsilon3 genotypes. The apoE genotype has been reported to account for approximately 10% of the variation of LDL cholesterol in the general population. It accounted for 15-60% of the variability of plasma LDL cholesterol or apoB levels in our FHBL subjects. The physiologic bases for the greater effects of apoE in FHBL remain to be determined.

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.atherosclerosis.2004.06.020DOI Listing

Publication Analysis

Top Keywords

ldl cholesterol
20
cholesterol apob
12
apob levels
12
apob
9
variability plasma
8
plasma low-density
8
low-density lipoprotein
8
levels fhbl
8
apob truncations
8
apob exon
8

Similar Publications

Background: Statin therapy lowers the risk of major adverse cardiovascular events (MACE) among people with HIV (PWH). Residual risk pathways contributing to excess MACE beyond low-density lipoprotein cholesterol (LDL-C) are not well understood. Our objective was to evaluate the association of statin responsive and other inflammatory and metabolic pathways to MACE in the Randomized Trial to Prevent Vascular Events in HIV (REPRIEVE).

View Article and Find Full Text PDF

Introduction:  Endothelial dysfunction has been reported in rheumatoid arthritis (RA) patients without classical cardiovascular risk factors, but findings remain inconsistent.

Objectives:  To assess whether endothelial function is impaired in RA with moderate inflammatory burden in the absence of established cardiovascular risk factors.

Patients And Methods:  This cross-sectional study was conducted in 64 patients with RA without classical CV risk factors and 60 healthy age- and sex-matched controls.

View Article and Find Full Text PDF

This study was conducted in a descriptive and cross-sectional design to determine the physical health status of individuals with substance use disorders receiving inpatient treatment at an addiction treatment center. Data were collected between April 2023 and April 2024 at the Adult Detoxification Center of a psychiatric hospital in Istanbul, Türkiye. The sample consisted of a total of 261 individuals with substance use disorders (218 males and 43 females) who met the inclusion criteria.

View Article and Find Full Text PDF

Are lipid-lowering drugs harmful to cognitive performance?: A Mendelian randomization study.

Medicine (Baltimore)

September 2025

Key Laboratory of Endocrine Glucose & Lipids Metabolism and Brain Aging, Ministry of Education; Department of Endocrinology, Shandong Provincial Hospital Affiliated to Shandong First Medical University, Jinan, Shandong Province, China.

Cardiovascular disease is the leading global cause of mortality, affecting the development of cognitive impairment in the elderly. Lipid-lowering drugs are commonly used to manage cardiovascular disease risk, but their effects on cognitive performance have produced conflicting results in previous research. To better guide the selective decision-making and application of lipid-lowering drugs, this study aims to determine the causal relationship between lipid-lowering drugs and cognitive performance through Mendelian randomization.

View Article and Find Full Text PDF

Cholesterol homeostasis dysregulation is a primary risk factor for atherosclerosis (AS) development. Fisetin, a flavonoid compound, has shown promise in regulating cholesterol homeostasis by enhancing transintestinal cholesterol excretion (TICE). This study aimed to investigate the regulatory effects and underlying mechanisms of fisetin in AS.

View Article and Find Full Text PDF